File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

TitleOutcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
Authors
KeywordsBrain metastases
Chemotherapy
Non‒small-cell lung cancer
PD-L1
Pembrolizumab
Issue Date2021
Citation
JTO Clinical and Research Reports, 2021, v. 2, n. 8, article no. 100205 How to Cite?
AbstractIntroduction: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive NSCLC to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the efficacy of pembrolizumab versus chemotherapy. Methods: We pooled the data for patients with previously treated or untreated PD-L1‒positive (tumor proportion score [TPS], ≥1%) advanced metastatic NSCLC in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894). Patients received pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 wk or 10 mg/kg every 2 wk); chemotherapy was a comparator in all studies except KEYNOTE-001. All studies included patients with previously treated, stable brain metastases. Results: A total of 3170 patients were included, 293 (9.2%) with and 2877 (90.8%) without baseline brain metastases; median (range) follow-up at data cutoff was 12.9 (0.1‒43.7) months. Pembrolizumab improved overall survival versus chemotherapy in patients with or without baseline brain metastases: benefit was seen in patients with PD-L1 TPS greater than or equal to 50% (0.67 [95% confidence intervals (CI): 0.44‒1.02] and 0.66 [95% CI: 0.58‒0.76], respectively) and PD-L1 TPS ≥1% (0.83 [95% CI: 0.62‒1.10] and 0.78 [95% CI: 0.71‒0.85], respectively). Progression-free survival was improved, objective response rates were higher, and the duration of response was longer with pembrolizumab versus chemotherapy regardless of brain metastasis status. The incidence of treatment-related adverse events with pembrolizumab versus chemotherapy was 66.3% versus 84.4% in patients with brain metastases and 67.2% versus 88.3% in those without. Conclusions: Pembrolizumab monotherapy improved outcomes and was associated with fewer adverse events than chemotherapy in patients with treatment-naive and previously treated PD-L1‒positive advanced/metastatic NSCLC regardless of the presence of baseline treated, stable brain metastases.
Persistent Identifierhttp://hdl.handle.net/10722/326509
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMansfield, Aaron S.-
dc.contributor.authorHerbst, Roy S.-
dc.contributor.authorde Castro, Gilberto-
dc.contributor.authorHui, Rina-
dc.contributor.authorPeled, Nir-
dc.contributor.authorKim, Dong Wan-
dc.contributor.authorNovello, Silvia-
dc.contributor.authorSatouchi, Miyako-
dc.contributor.authorWu, Yi Long-
dc.contributor.authorGaron, Edward B.-
dc.contributor.authorReck, Martin-
dc.contributor.authorRobinson, Andrew G.-
dc.contributor.authorSamkari, Ayman-
dc.contributor.authorPiperdi, Bilal-
dc.contributor.authorEbiana, Victoria-
dc.contributor.authorLin, Jianxin-
dc.contributor.authorMok, Tony S.K.-
dc.date.accessioned2023-03-10T02:19:47Z-
dc.date.available2023-03-10T02:19:47Z-
dc.date.issued2021-
dc.identifier.citationJTO Clinical and Research Reports, 2021, v. 2, n. 8, article no. 100205-
dc.identifier.urihttp://hdl.handle.net/10722/326509-
dc.description.abstractIntroduction: We retrospectively evaluated outcomes in patients with programmed death-ligand 1 (PD-L1)–positive NSCLC to determine whether baseline (i.e., at study enrollment) brain metastases were associated with the efficacy of pembrolizumab versus chemotherapy. Methods: We pooled the data for patients with previously treated or untreated PD-L1‒positive (tumor proportion score [TPS], ≥1%) advanced metastatic NSCLC in KEYNOTE-001 (NCT01295827), KEYNOTE-010 (NCT01905657), KEYNOTE-024 (NCT02142738), and KEYNOTE-042 (NCT02220894). Patients received pembrolizumab (2 mg/kg, 10 mg/kg, or 200 mg every 3 wk or 10 mg/kg every 2 wk); chemotherapy was a comparator in all studies except KEYNOTE-001. All studies included patients with previously treated, stable brain metastases. Results: A total of 3170 patients were included, 293 (9.2%) with and 2877 (90.8%) without baseline brain metastases; median (range) follow-up at data cutoff was 12.9 (0.1‒43.7) months. Pembrolizumab improved overall survival versus chemotherapy in patients with or without baseline brain metastases: benefit was seen in patients with PD-L1 TPS greater than or equal to 50% (0.67 [95% confidence intervals (CI): 0.44‒1.02] and 0.66 [95% CI: 0.58‒0.76], respectively) and PD-L1 TPS ≥1% (0.83 [95% CI: 0.62‒1.10] and 0.78 [95% CI: 0.71‒0.85], respectively). Progression-free survival was improved, objective response rates were higher, and the duration of response was longer with pembrolizumab versus chemotherapy regardless of brain metastasis status. The incidence of treatment-related adverse events with pembrolizumab versus chemotherapy was 66.3% versus 84.4% in patients with brain metastases and 67.2% versus 88.3% in those without. Conclusions: Pembrolizumab monotherapy improved outcomes and was associated with fewer adverse events than chemotherapy in patients with treatment-naive and previously treated PD-L1‒positive advanced/metastatic NSCLC regardless of the presence of baseline treated, stable brain metastases.-
dc.languageeng-
dc.relation.ispartofJTO Clinical and Research Reports-
dc.subjectBrain metastases-
dc.subjectChemotherapy-
dc.subjectNon‒small-cell lung cancer-
dc.subjectPD-L1-
dc.subjectPembrolizumab-
dc.titleOutcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042-
dc.typeConference_Paper-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jtocrr.2021.100205-
dc.identifier.scopuseid_2-s2.0-85112615261-
dc.identifier.volume2-
dc.identifier.issue8-
dc.identifier.spagearticle no. 100205-
dc.identifier.epagearticle no. 100205-
dc.identifier.eissn2666-3643-
dc.identifier.isiWOS:001137466100004-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats